Genes | Genomes | Genetics

Essential domains of S. pombe Rad8 required for DNA damage response

Lin Ding* and Susan L Forsburg*

*Program in Molecular & Computational Biology, University of Southern California Los Angeles, CA 90089-2910

Corresponding Author: Susan L Forsburg

Address: Program in Molecular & Computational Biology, University of Southern California, 1050 Childs Way, Los Angeles, CA 90089-2910 Phone 213-740-7342 Email: forsburg@usc.edu

DOI: 10.1534/g3.114.011346

Table S1 Yeast strains used in this study

Strain number	Genotype	Source
FY11	h- ade6-M210	Our stock
FY528	h+ his3-D1 ura4-D18 leu1-32 ade6-M210	Our stock
FY527	h- his3-D1 ura4-D18 leu1-32 ade6-M216	Our stock
FY5627	h- ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5698	h- ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5625	h+ ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5699	, h+ ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY444	h+ rad8-190 ura4-D18 leu1-32 ade6-704	Our stock
FY1884	h- smt-0 ∆rad51::ura4+ ura4-D18 leu1-32 ade6-M210	Our stock
FY6785	h- smt-0 ∆rad51::ura4+ ∆rad8::hphMX ura4-D18 leu1-32 ade6-M210	This study
FY1866	h- smt-0 ∆rad54::ura4+ ura4-D18 leu1-32 ade6-M216	Our stock
FY6868	h- smt-0 ∆rad54::ura4+ ∆rad8::hphMX ura4-D18 leu1-32 ade6-M216	This study
FY1389	h- smt-0 ∆rad55::ura4+ ura4-D18	Our stock
FY6809	h- smt-0 ∆rad55::ura4+ ∆rad8::hphMX ura4-D18 ade6-M216	This study
FY3770	h- smt-0 ∆rad57::ura4+ his3-D1 ura4-D18 leu1-32 ade6-M210	Our stock
FY6790	h- smt-0 ∆rad57::ura4+ ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study AW525 (Hu et al.,
FY6397	h- loxP-dna2-K961T-loxM3 ura4-D18 leu1-32 ade6-704	2012)
FY6428	h- loxP-dna2-K961T-loxM3 ∆rad8∷hphMX his3-D1 ura4-D18 leu1-32 ade6-M216 h- dna2ts:ura4_ura4-D18	This study This study (Hu et al., 2012)
FY6505	h- dna2ts:ura4 \rad8::hphMX his3-D1 ura4-D18 ade6-M216	This study
FY254	h- ura4-D18 leu1-32 ade6-M210 can1-1	Our stock
FY6314	h- loxP-rad8 ⁺ -loxM3 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6322	h- loxP-∆rad8-loxM3 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6316	h- loxP-rad8-∆HIRAN-loxM3 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6514	h- loxP-rad8∆HIRAN::SV40NLS-loxM3 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6516	h- loxP-rad8∆HIRAN::rad8NLS-loxM3 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6518	h- loxP-rad8-∆NLS-loxM3 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6520	h- loxP-rad8-HIRAN-loxM3 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6318	h- loxP-rad8-K535AT536A-loxM3 leu1-32 ade6-M210 can1-1	This study
FY6320	h- loxP-rad8-I879A-loxM3 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6284	h- loxP-rad8-K535AT536AI879A-loxM3	This study
FY7012	h- loxP-rad8 ⁺ -5FLAG::KanMX6 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY6905	h- loxP-rad8-K535AT536A-5FLAG::KanMX6	This study

FY6959	h- loxP-rad8-I879A- 5FLAG::KanMX6 ura4-D18 leu1-32 ade6-M210 can1-1	This study
FY5904	h ⁻ rad8-5FLAG::kanMX6	This study
FY3123	h- ∆rhp18::ura4+ ura4-D18 leu1-32 ade6-704	Our stock
FY6617	h- ∆rhp18::ura4+ ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M704	This study
FY6628	h- ∆mms2::leu2 his3-D1 ura4-D18 leu1-32 ade6-M210	Our stock
FY6619	h- ∆mms2::leu2 ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY6929	h- pcn1-K164R::ura4+ his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY6115	h- pcn1-K164R::ura4+ ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY6816	h- pcn1-K164R::ura4+ loxP-rad8-K535AT536A-loxM3 his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY6875	h- pcn1-K164R::ura4+ loxP-rad8-I879A-loxM3 his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5128	h- ∆srs2::kan his3-D1 ura4-D18 leu1-32 ade6-M210	Our stock
FY5744	h- ∆srs2::kan ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY4841	h- eso1::kanMX6 kpa1::bleMX6 rev3::hphMX6 his3-D1 ura4-D18 leu1-32 ade6-M216	Our stock
FY6863	h- eso1::kanMX6 kpa1::bleMX6 rev3::hphMX6 ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study This study From MCW2080 (Sun et al.,
FY5555	h- ∆fml1::natMX4 his3-D1 ura4-D18 leu1-32	2008)
FY6436	h- ∆fml1::natMX4 ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5587	h- ∆fml2:kanMX6-Bioneer his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5726	h- ∆fml2:kanMX6-Bioneer ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study This study From MCW2082 (Sun et al.,
FY6936	h- ∆fml1::natMX4 ∆fml2::KanMX6 his3-D1 ura4-D18 leu1-32	2008)
FY5717	h- ∆fml1::natMX4 ∆fml2::KanMX6 ∆rad8::hphMX his3-D1 ura4-D18 leu1-32	This study
FY6764	h- ∆fml1::natMX4 ∆fml2::KanMX6 loxP-rad8-K535AT536A-loxM3 ura4-D18 leu1-32	This study
FY6759	h- ∆fml1::natMX4 ∆fml2::KanMX6 loxP-rad8-K535AT536Al879A-loxM3 ura4-D18 leu1-32 ade6-M210	This study
FY6766	h- ∆fml1::natMX4 ∆fml2::KanMX6 loxP-rad8-l879A-loxM3 his3-D1 ura4-D18 leu1-32 h- pcn1-K164R::ura4+ ∆fml1::natMX4 ∆fml2::KanMX6 loxP-rad8-K535AT536A-loxM3 his3-D1 ura4-D18 leu1-32	This study
FY6825	ade6-M210	This study
FY6826	h- pcn1-K164R::ura4+ ∆fml1::natMX4 ∆fml2::KanMX6 ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study This study From MCW2080 (Sun et al.,
FY6257	h- ∆fml1::natMX4 his3-D1 ura4-D18 leu1-32 ade6-M216	2008)
FY6941	h- pcn1-K164R::ura4+ ∆fml1::natMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study This study From
FY6948	h- ∆fml2::KanMX6 ura4-D18 leu1-32 ade6-M210	MCW2082

		(Sun et al., 2008)
FY6946	h- pcn1-K164R::ura4+ ∆fml2::KanMX6 his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY6932	h- pcn1-K164R::ura4+ ∆fml1::natMX4 ∆fml2::KanMX6 his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY2732	h- ∆rad32::kanMX ura4-D18 leu1-32 ade6-M210	Our stock
FY5892	h- ∆rad32::kanMX ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY2733	h- ∆rad50∷kanMX ura4-D18 leu1-32 ade6-M210	Our stock
FY5888	h- ∆rad50::kanMX ∆rad8::hphMX ura4-D18 leu1-32 ade6-M216	This study
FY2734	h- ∆nbs1::kanMX ura4-D18 leu1-32	Our stock
FY5895	h- ∆nbs1::kanMX ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5428	h- ∆exo1::ura4+ ura4-D18 ade6-M210	Our stock
FY6141	h- ∆exo1::ura4+ ∆rad8::hphMX ura4-D18 ade6-M210	This study
FY6820	h- ∆exo1::ura4+ loxP-rad8-K535AT536A-loxM3 his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY6879	h- ∆exo1::ura4+ loxP-rad8-l879A-loxM3 his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY790	h- rad11A-ts ura4-D18 leu1-32 ade6-M216	Our stock
FY6797	h- rad11A-ts ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY3288	h- ∆mus81::KanMX ura4-D18 ade6-M210	Our stock
FY6118	h- ∆mus81::KanMX ∆rad8::hphMX his3-D1 ura4-D18 ade6-M210	This study
FY865	h- ∆cds1::ura4 ura4-D18 leu1-32	Our stock
FY5739	h- ∆cds1::ura4+ ∆rad8::hphMX ura4-D18 leu1-32	This study
FY6906	h- ∆cds1::ura4 loxP-rad8-K535AT536A-loxM3 ura4-D18 leu1-32 ade6-M216	This study
FY6897	h- ∆cds1::ura4 loxP-rad8-I879A-loxM3 ura4-D18 leu1-32 ade6-M216	This study
FY4685	h- ∆mrc1::kanMX6-Bioneer his3-D1 ura4-D18 leu1-32 ade6-?	Our stock
FY5742	h- Δ mrc1::kanMX6-Bioneer Δ rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY3529	h+ ∆mrc1::ura4+ leu1+::(mrc1(all S/TQ to AQ)-3HA) ura4-D18 ade6?	Our stock
FY5885	h- ∆mrc1::ura4+ leu1+::(mrc1(all S/TQ to AQ)-3HA) ∆rad8::hphMX his3-D1 ura4-D18 ade6-M210	This study
FY3229	h- ∆swi3::KanMX ura4-D18 leu1-32 ade6-M210	Our stock
FY5784	h- ∆swi3::KanMX ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY3226	h- ∆swi1∷kanMX his3-D1 ura4-D18 leu1-32 ade6-M210	Our stock
FY5783	h- ∆swi1::KanMX ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY6812	h- ∆swi1::KanMX loxP-rad8-K535AT536A-loxM3 his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY6871	h- ∆swi1::KanMX loxP-rad8-l879A-loxM3 ura4-D18 leu1-32 ade6-M210	This study
FY6821	h- ∆swi1::kanMX pcn1-K164R::ura4 his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY6400	h- ∆rad8::hphMX his3-D1 ura4-D18 ade6-M210	This study
FY6370	h- ∆rad8::hphMX leu1-32::(nmt1-rad8-K535AT536A-GFP-leu1+) his3-D1 ura4-D18 ade6-M210	This study
FY6372	h- ∆rad8::hphMX leu1-32::(nmt1-rad8-I879A-GFP-leu1+) his3-D1 ura4-D18 ade6-M210	This study
FY6374	h- ∆rad8::hphMX leu1-32::(nmt1-rad8-K535AT536l879A-GFP-leu1+) his3-D1 ura4-D18 ade6-M21	0 This study
FY6402	h- Δ rad8::hphMX leu1-32::(nmt1-rad8- Δ HIRAN-GFP-leu1+) his3-D1 ura4-D18 ade6-M210	This study
FY6522	h- ∆rad8::hphMX leu1-32::(nmt1-rad8∆HIRAN::SV40NLS-GFP-leu1+) his3-D1 ura4-D18 ade6-M21	0 This study
FY6524	h- ∆rad8::hphMX leu1-32::(nmt1-rad8∆HIRAN::rad8NLS-GFP-leu1+) his3-D1 ura4-D18 ade6-M210) This study

FY6526	h- ∆rad8::hphMX leu1-32::(nmt1-rad8-no-NLS-GFP-leu1+) his3-D1 ura4-D18 ade6-M210	This study
FY6528	h- ∆rad8::hphMX leu1-32::(nmt1-rad8-HIRAN-GFP-leu1+) his3-D1 ura4-D18 ade6-M210	This study
FY3779	h- ∆fbh1::kanMX leu1-32 ura4-D18	Our stock
FY5731	h- ∆fbh1::kanMX ∆rad8::hphMX ura4-D18 leu1-32 ade6-M216	This study
FY5745	h- ∆tlh2::kanMX6-Bioneer his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5746	h+ ∆tlh2::kanMX6-Bioneer ∆rad8::hphMX leu1-32 ura4-D18 ade6-M216	This study
FY5747	h- ∆swr1::kanMX6-Bioneer his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5748	h- ∆swr1::kanMX6-Bioneer ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5749	h- ∆SPAC144.05::kanMX6-Bioneer leu1-32 ura4-D18 ade6-M210	This study
FY5750	h+ ∆SPAC144.05::kanMX6-Bioneer ∆rad8::hphMX leu1-32 ura4-D18 ade6-M210	This study
FY5751	h+ ∆rrp1::kanMX6-Bioneer leu1-32 ura4-D18 ade6-M210	This study
FY5752	h- ∆rrp1::kanMX6-Bioneer ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5753	h+ ∆rdh54::kanMX6-Bioneer his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5754	h- ∆rdh54::kanMX6-Bioneer ∆rad8::hphMX leu1-32 ura4-D18 ade6-M210	This study
FY5755	h- ∆chl1::kanMX6-Bioneer leu1-32 ura4-D18 ade6-M210	This study
FY5756	h+ ∆chl1::kanMX6-Bioneer ∆rad8::hphMX leu1-32 ura4-D18 ade6-M210	This study
FY5757	h- ∆SPAC694.02::kanMX6-Bioneer leu1-32 ura4-D18 ade6-M210	This study
FY5758	h+ Δ SPAC694.02::kanMX6-Bioneer Δ rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5759	h- ∆SPBC15C4.05::kanMX6-Bioneer his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5760	h+ ∆SPBC15C4.05::kanMX6-Bioneer ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5761	h+ ∆rrp2::kanMX6-Bioneer leu1-32 ura4-D18 ade6-M210	This study
FY5762	h- ∆rrp2::kanMX6-Bioneer ∆rad8::hphMX leu1-32 ura4-D18 ade6-M216 his3-D1	This study
FY5763	h+ ∆hrp1::kanMX6-Bioneer leu1-32 ura4-D18 ade6-M216 his3-D1	This study
FY5764	h+ ∆hrp1::kanMX6-Bioneer ∆rad8::hphMX leu1-32 ura4-D18 ade6-M210	This study
FY5765	h- ∆rhp26::kanMX6-Bioneer leu1-32 ura4-D18 ade6-M210	This study
FY5766	h+ ∆rhp26::kanMX6-Bioneer ∆rad8::hphMX leu1-32 ura4-D18 ade6-M216	This study
FY5767	h+ ∆irc3::kanMX6-Bioneer leu1-32 ura4-D18 ade6-M210	This study
FY5768	h- ∆irc3::kanMX6-Bioneer ∆rad8::hphMX his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5769	h- ∆SPBC582.10C::kanMX6-Bioneer his3-D1 ura4-D18 leu1-32 ade6-M210	This study
FY5770	h+ ∆SPBC582.10C::kanMX6-Bioneer ∆rad8::hphMX ura4-D18 leu1-32 ade6-M210	This study
FY5771	h+ ∆SPCC737.07c::kanMX6-Bioneer his3-D1 ura4-D18 leu1-32 ade6-M216	This study
FY5772	h+ ∆SPCC737.07c::kanMX6-Bioneer ∆rad8::hphMX ura4-D18 leu1-32 ade6-M210	This study
FY5773	h- ∆hrp3::kanMX6-Bioneer his3-D1 leu1-32 ura4-D18 ade6-M216	This study
FY5774	h- ∆hrp3::kanMX6-Bioneer ∆rad8::hphMX ura4-D18 leu1-32 ade6-M210	This study
FY4777	h- ∆snf22::KanMX ura4-D18 leu1-32	This study
FY5779	h- ∆snf22::KanMX ∆rad8::hphMX his3-D1 ura4-D18 leu1-32	This study HT21 (Boule and Zakian,
FY4703	h- pfh1-R20 leu1-32	2006)

FY6483	h- pfh1-R20 ∆rad8::hphMX ura4-D18 leu1-32 ade6-M216	This study
FY6337	h- ∆rad8::hphMX ade6-M210	This study
FY6434	h- rad8-GFP::kanMX6 ade6-M210	This study
FY2194	h- ∆rad3::ura4+ ura4-D18 ade6-M216	Our stock
FY6315	h- loxP-rad8⁺-loxM3 leu1-32 ade6-M210 ura4-D18 can1-1	This study
FY6317	h- loxP-rad8-∆HIRAN-loxM3 leu1-32 ade6-M210 ura4-D18 can1-1	This study
FY6319	h- loxP-rad8-K535AT536A-loxM3 leu1-32 ade6-M210 ura4-D18 can1-1	This study
FY6321	h- loxP-rad8-1879A-loxM3 leu1-32 ade6-M210 ura4-D18 can1-1	This study
FY6284	h- loxP-rad8-K535AT536AI879A-loxM3 leu1-32 ade6-M210 ura4-D18 can1-1	This study
FY6323	h- loxP-∆rad8-loxM3 leu1-32 ade6-M210 ura4-D18 can1-1	This study
FY6394	h- loxP-rad8-S18D-loxM3 leu1-32 ade6-M210 ura4-D18 can1-1	This study
FY6399	h- loxP-rad8-S18A-loxM3 leu1-32 ade6-M210 ura4-D18 can1-1	This study

Table S2 Plasmids used in this study

Plasmid	Purpose	Source
pAW1	To construct <i>lox</i> -Cre base strain for <i>rad8</i> è FY5622	EUROSCARF: P30537
pAW8-Xhol	To make swap the <i>loxP loxM3</i> flanked region in the genome of FY5622	EUROSCARF: P30585
pLD45	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8</i> ⁺	This study
pLD46	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8-∆HIRAN</i>	This study
pLD47	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8-K535AT536A</i>	This study
pLD48	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8-l879A</i>	This study
pLD49	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8-K535AT536AI879A</i>	This study
pLD99	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8-∆HIRAN::SV40NLS</i>	This study
pLD100	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8-∆HIRAN::Rad8NLS</i>	This study
pLD101	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8-∆NLS</i>	This study
pLD102	To make swap the <i>loxP loxM3</i> flanked region in FY5622 with <i>rad8-HIRAN</i>	This study
pJK148	Integration at <i>leu1-32</i> locus	Our stock
pLD52	To integrate <i>rad8</i> ⁺ - <i>GFP</i> into <i>leu1-32</i> locus	This study
pLD54	To integrate rad8-K535AT536A-GFP into leu1-32 locus	This study
pLD55	To integrate rad8-I879A-GFP into leu1-32 locus	This study
pLD56	To integrate rad8- K535AT536AI879A-GFP into leu1-32 locus	This study
pLD53	To integrate <i>rad8-</i> ∆ <i>HIRAN-GFP</i> into <i>leu1-32</i> locus	This study
pLD96	To integrate <i>rad8-∆HIRAN::SV40NLS-GFP</i> into <i>leu1-32</i> locus	This study
pLD96	To integrate rad8-∆HIRAN::Rad8NLS-GFP into leu1-32 locus	This study
pLD97	To integrate <i>rad8-∆NLS-GFP</i> into <i>leu1-32</i> locus	This study
pLD98	To integrate rad8-HIRAN-GFP into leu1-32 locus	This study

Group	genotype	orthologs	growth	HU	MMS	UV	CPT
1:	∆rhp26	hXRCC3	-	-	\downarrow	-	\downarrow
MMS	ScRad26						
specific	∆rad8	HLTF, SHPRH	-	-	$\downarrow\downarrow$	\downarrow	-
		ScRad8					
	∆hrp1	hCHD1, 2	-	-	-	-	$\downarrow\downarrow$
2: response		ScChd1					
to protein	∆swr1	hEP400, hSRCAP					
barriers		ScSwr1	-	-	-	-	$\downarrow\downarrow$
	∆SPBC15C4.05#	hDHX29	-	-	-	-	$\downarrow\downarrow\downarrow\downarrow$
	∆snf22	hSMARCA4					
3:		ScSth1, ScSnf2	-	$\downarrow\downarrow$	-	-	\downarrow
regulates	∆srs2	ScSrs2	-	↓	-	-	\downarrow
HR	∆SPAC694.02*	hDDX60, hDDX60L	-	$\downarrow\downarrow$	-	-	$\downarrow\downarrow\downarrow\downarrow$
	∆chl1	hFANCJ	-	\downarrow	\downarrow	\downarrow	\downarrow
		ScChl1					
	∆fml1	hFANCM	-	\downarrow	$\downarrow\downarrow$	\downarrow	\downarrow
		ScMph1					
4:	∆fbh1	hFBXO18	-	↓	$\downarrow\downarrow$	$\downarrow\downarrow$	\downarrow
HR-	∆rqh1	hWRN, hBLM	-	$\downarrow\downarrow$	$\downarrow\downarrow$	$\downarrow\downarrow\downarrow\downarrow$	$\downarrow\downarrow\downarrow\downarrow$
associated		ScSgs1					
	∆rad54	hRAD54L	\downarrow	$\downarrow\downarrow$	↓↓↓	$\downarrow\downarrow$	$\downarrow\downarrow\downarrow\downarrow$
		SCRad54					
	∆rad57	NXRCC3	-	↓	$\downarrow\downarrow$	Ļ	$\downarrow\downarrow\downarrow\downarrow$
	A bree 2						
	Anrp3	NCHD1, NCHD2	-	-	-	-	-
	A final O		_				
	ΔΠΠΖ		-	-	-	-	-
	Arro1						
5.	Δπρτ		-	-	-	-	-
no	Arro?		_	_	_	_	_
phenotype		Schlis1	-	-	-	-	-
	ASPBC3B8 12*	Scirc3	_	1_		-	_
	ASPBC582 10C	ScRad16	_	1_		-	_
	∆rdh54	hRAD54B					
		ScRdh54	_	_	-	_	_
	ASPCC737.07c	hIGHMBP2	-	-	_	_	_
		ScHcs1					
	∆tlh2	NA	-	-	-	-	-
	∆SPAC144.05	hSHPRH	-	-	-	-	-
		ScIRC20					
	∆rad55	hRAD51B	-	-	-	-	-
		ScRad55					

Table S3 An analysis of the drug sensitivity of non-essential helicase mutants

The level of sensitivity is scored by the fitness on the drug plates. No difference from wildtype is labeled as "-". The level of sickness is scored by number of " \downarrow ". NA = not available. h = Homo sapiens. Sc = *Saccharomyces cerevisiae*. HR = Homologous recombination. # RNA/DNA helicase. * RNA helicase. SPBC3B8.12 = SPBC11C11.11c.

	genotype	growth	HU	MMS	UV	CPT
	Δhrp3 Δrad8	-	-	-	-	-
	$\Delta t lh2 \Delta rad8$	-	-	-	-	-
	$\Delta hrp1 \Delta rad8$	-	-	-	-	-
	Δswr1 Δrad8	-	-	-	-	-
	$\Delta rdh54 \Delta rad8$	-	-	-	-	-
	∆rrp1 ∆rad8	-	-	-	-	-
	$\Delta rrp2 \Delta rad8$	-	-	-	-	-
	∆SPBC3B8.12 ∆rad8	-	-	-	-	-
no synthetic	∆SPBC15C4.05 ∆rad8	-	-	-	-	-
delects	∆SPBC582.10C ∆rad8	-	-	-	-	-
	∆SPAC694.02 ∆rad8	-	-	^\$	-	-
	∆ SPCC737.07c ∆rad8	-	-	-	-	-
	∆SPAC144.05 ∆rad8	-	-	-	-	-
	cdc21-M68 ∆rad8	-	-	-	-	-
	cdc21-C84 ∆rad8	-	-	-	-	-
	∆rhp26 ∆rad8	-	-	$\downarrow\downarrow$	-	-
	∆fbh1 ∆rad8	-	-	Ļ	↓	-
	∆rqh1 ∆rad8	-	↓	$\downarrow\downarrow$	↓	ND
Increased	∆rad54 ∆rad8	\downarrow	$\downarrow\downarrow\downarrow\downarrow$	$\downarrow\downarrow$	↓	\downarrow
drug	∆rad55 ∆rad8	\downarrow	↓	$\downarrow\downarrow$	$\downarrow\downarrow$	$\downarrow\downarrow$
sensitivity	∆rad57 ∆rad8	-	↓	$\downarrow\downarrow$	↓	\downarrow
	pfh1-R20 ∆rad8	-	↑	Ļ	-	-
	dna2-K961T∆rad8	-	↓	$\downarrow\downarrow$	↓	ND
	dna2 ^{ts} ∆rad8	-	-	Ļ	↓	-
	∆fml1 ∆rad8	-	$\downarrow\downarrow$	↓↓	$\downarrow\downarrow$	$\downarrow\downarrow$
	$\Delta fml2 \Delta rad8$	-	-	\downarrow	-	-
	∆fml1 ∆fml2 ∆rad8	-	$\downarrow\downarrow$	$\downarrow\downarrow\downarrow\downarrow$	$\downarrow\downarrow$	↑
		elongated				
mixed drug	∆chl1 ∆rad8	-	-	$\downarrow\downarrow$	-	1
sensitivity	∆srs2 ∆rad8	-	1	Ļ	-	$\downarrow\downarrow$
	Δ snf22 Δ rad8	-	1	-	-	↓

Table S4 A survey of rad8 genetic interaction with helicase mutants on different drugs

The level of sensitivity is scored by the fitness on the drug plates. No difference from the either of the single mutants is labeled as "-". The level of increased drug sensitivity is scored by number of " \downarrow ". The level of reduced drug sensitivity is scored by number of " \uparrow ". ND = not determined. \$ one RNA helicase partially decreased the MMS sensitivity of rad8. SPBC3B8.12 = SPBC11C11.11c.



Figure S1 S18 is not required for Rad8 DNA damage response. Strains were grown overnight at 32°C, 1:5 serially diluted and spotted to plain YES rich medium (Control) and YES with indicated drugs. Plates were incubated at 32°C for 3 days.



Figure S2 Overproduction of *rad8* in *Δrad8* has minor defects. (A) Overproduction (EMM-LEU plate) of *rad8-GFP* causes slightly growth defect. Strains were streaked out on different medium according to the schematics. (B) *rad8-GFP* fully complements $\Delta rad8$ and cells mount the same response to damaging drugs in the presence of thiamine (YES). Strains were grown overnight at 32°C, 1:5 serially diluted and spotted to plain YES rich medium (Control) and YES with indicated drugs. (C) Overproduction of *rad8-GFP* and mutants is slightly toxic to cells. Strains were grown overnight at 32°C, washed twice with EMM-LEU medium, 1:5 serially diluted in EMM-LEU and spotted to EMM-LEU medium (Control) and EMM-LEU with indicated drugs. Plates were incubated at 32°C for 3 days if not indicated.

Fig.S3						
Α		M	ИS			
Control	10mM HU	0.005%	0.0075%	100J/m ²	10μ Μ CPT	
	• • •				• • • *	WT
$\bullet \bullet \bullet \bullet$		• • • •	- 🔄 🔆	🔴 🕲 😂 🄅	• • •	⊿rad8
		🙆 🍪 🖒 🏤		3 🧐 -		∆rhp18
$\bullet \bullet \bullet \bullet$	• • *	🧶 🏶 🔅 👘		 * * 	🌒 🏟 🚳 jej	∆rhp18 ∆rad8
		🕘 🍪 🏶 👘	. @ S C	• • • •		⊿mms2
	Q @ & ``	💓 🕸 🏶 🔅				⊿mms2 ⊿rad8
B Control	10mM HU 0	.0075% MMS	5 100J/m ²	10μ Μ CPT		
					WT	
0 0 0 A	•• •	۰ ج ک	ې 🛧 🏶 🌢	• • • •	⊿rad8	
	• • • *	🗢 🏶 🐄 👳	• • • • •	• • • •	⊿eso1 ∆kpa1	⊿rev3
	() () () () () () () () () () () () () () ()			🜔 🏶 🏶 K	∆eso1 ∆kpa1	⊿rev3 ⊿rad8

Figure S3 Rad8 functions in the PRR pathway. (A) *rad8* Δ is epistatic with *rhp18* Δ and *mms2* Δ . Strains were grown overnight at 32°C, 1:5 serially diluted and spotted to plain YES rich medium (Control) and YES with indicated drugs. (B) *rad8* Δ is not epistatic with TLS mutants. Strains were grown overnight at 32°C, 1:5 serially diluted and spotted to plain YES rich medium (Control) and YES with indicated drugs. Plates were incubated at 32°C for 3 days.

Fig.S4

54							
Control	10mM HU	0.01% MMS	150J/m ²	15µM CPT			
	6 8 8 /				WT		
	•••			ତ୍ତ୍ର ବୋଦ ଜନ୍ମ ଦେଇ	⊿rad8 Abro1		
		*			Ahro1 Arad8		
	• • • •	• • • · ·		0883	∆rhp26		
	 · · · · · · · · · · · · · · · · · · ·		• • •	0.000	⊿rhp26 ⊿rad	8	
				• • • • • • • ≫	△SPBC3B8.	12 12 Arod 9	
Control	10mM HU	0.01% MM	1E0 1/m2	15. M CDT	23F 00300.	12 2/800	
		0.01% WIWS		15µW CPT	WT		
					⊿rad8		
					∆tlh2		
				000	⊿tin∠ ∆rad8 ∆swr1		
				0.	∆swr1 ∆rad8	}	
	• • * * ÷			• • • •	∆SPAC144.	05	
		10			△SPAC144.0	05 ⊿rad8	
Control	10mM HU	0.01% MMS	150J/m ²	15µM CPT	WT		
					⊿rad8		
	• • • · ·				∆rrp1		
			9		∆rrp1 ∆rad8		
			b b c		⊿rdn54 ∆rdh54 ∆rad	18	
Control	10mM HU	0.01% MMS	150.l/m ²	15uM CPT			
	10 0 0 c	0000		A 6 6 6	WT		
	•• @ @ &	4	83		⊿rad8		
				<u>ଜ୍</u> ନ୍ନେ ଓଡ଼ିଜ୍ନ	△SPAC694.0	02 02 4rod 8	
	• • •			* 8 \$ \$	△SPBC15C4	1.05	
	● ୭`୫ ଟ	\$. ···	•	0.04	∆SPBC15C4	4.05 <i>∆rad8</i>	
	• 68.48 m.	0004		* 8 * *	∆rrp2		
		150.11 2					
Control	10mM HU	150J/m²	15µM CPT	Control	0.01% MMS	WT	
						∆rad8	
	• • • *			••**		∆SPBC582.1	0C
	● ● ● ● ≈					△SPBC582.1	0C Arad8
					4.2	⊿SPCC737.0)7c ∆rad8
•••			• • • • •	••**		∆hrp3	
		A B H H	6000		12 ·	∆hrp3 ∆rad8	
Control	7.5mM HU	10mM HU	200J/m ²	10µM CPT	Control	0.01% MMS	IA/T
							∆rad8
		0					Asnf22
		200		2000			∆snf22 ∆rad8
Control	10mM HU	0.0025% MM	S 100J/m ²	10µM CPT			
6000				00.04	WT		
	••**				⊿rad8		
					⊿fbh1		
					⊿tbh1 ∆rad8		
Control	4mM HU	0.005% MMS	100J/m ²	10µM CPT	luce		
					vv I ∆rad8		
		3 0 1		19.5	pfh1-R20		
• • • *		9	8 7 1		pfh1-R20 ∆r	ad8	
				0000	⊿chl1		
		Sec. 37	N. 19 19 14	St. 1. 69 55 55	Achl1 Arad8		



Control	50J/m ²	1µM CPT	
			WT
			Arad8
			Amre11 Arad8
			∆rad50
			Arad50 Arad8
	4		Anbs1 Arad8
Control	0.1µM CPT	10µM CPT	Control 100J/m ² 20µM CPT
			W T
			●●●●● ● ● ● ● ● ● ● ● ● △ △ △ Arad8
	• • •		△exo1 rad8-LD ∠mre11
	0 8 8 8	0. 5 .	∆mre11 ∆exo1
Control	100J/m ²		
		WT Arad R	
		dna2-K961T	
	Se	dna2-K961T	∆rad8
Control	100J/m ²	10µM CPT	
HH			WT
			drad8 dra2 ^{ts}
	4 17 × ·		dna2 ^{ts} ∆rad8
Control	100J/m ²	15µM CPT	
HHH			WT Arad R
	• • • •		rad11A ^{ts}
	Ó		rad11A ^{ts} ∆rad8
Control	100J/m ²	10µM CPT	Lucz.
			Arad8
		စ္ခန္း	Acds1
		8.000	Acds1 Arad8
			Acds1 rad8-LD
Control	150J/m ²	2µM CPT	
			WT
			∆rad8 Amrc1
			∆mrc1 ∆rad8
			mrc1-AQ
			mrc1-AQ Δrad8 Aswi3
		Q 0 0 0 0	∆swi3 ∆rad8
Control	100J/m ²	2µM CPT	
			WT Arad8
			∆swi1
	4) A		∆swi1 ∆rad8
		000	Aswi1 rad8-HD Aswi1 rad8-LD
			pcn1-K164R
			pcn1-K164R ∆swi1

Figure S4 A damage fingerprint of helicase mutants Strains were grown overnight at 32°C or 25°C for ts strains, 1:5 serially diluted and spotted to plain YES rich medium (Control) and YES with indicated drugs. Plates were incubated at 32°C for 3 days or 25°C for 5 days.



Figure S5 Fml1 and Rad8 ligase domain are functionally redundant. Strains were grown overnight at 32°C, 1:5 serially diluted and spotted to plain YES rich medium (Control) and YES with indicated drugs. Plates were incubated at 32°C for 3 days.

FigS6



Figure S6 A comparison of the sensitivity of homologues recombination mutants to HU. Strains were grown overnight at 32°C, 1:5 serially diluted and spotted to plain YES rich medium (Control) and YES with indicated drugs. Plates were incubated at 32°C for 3 days unless otherwise indicated.